

REMARKS

Amendments to the Specification

The specification has been amended to update information relating to applications from which the subject application claims priority. These amendments do not add new matter. Their entry is respectfully requested.

Amendments to the Claims

Claims 1-3 and 5-22 have been canceled, without prejudice.

Claim 4 has been amended to recite:

“A method of treating a patient having sepsis or septic shock, comprising administering to said patient an antibody or an antigen-binding fragment thereof that specifically binds to an isolated or recombinant polypeptide comprising the amino acid sequence of SEQ ID NO: 8 or an antigenic fragment thereof.”

Support for this amendment may be found, *inter alia*, on page 78, lines 12 and 19, of the specification as originally filed, and in original claims 15-18.

New claims 23-24 have been added.

Support for new claim 23 may be found, *inter alia*, on page 47, line 31, of the specification as originally filed.

Support for new claim 24 may be found, *inter alia*, on page 47, line 30, of the specification as originally filed.

Use of Prior Sequence Submission Under C.F.R. §1.821(e) and (f)

The present application claims priority to U.S. Patent Application No. 11/844,179. A copy of the paper Sequence Listing from U.S. Patent Application No. 11/844,179 filed concurrently herewith. In lieu of filing a computer readable form (“CRF”) of the Sequence Listing in the present application, Applicants request that the Patent and Trademark Office use the CRF of the Sequence Listing in parent U.S. Patent Application No. 11/844,179. It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the instant application. The paper copy of the Sequence Listing is the same as the CRF of the Sequence Listing in U.S. Patent Application No. 11/844,179.

CONCLUSION

Applicants believe that the present application is in condition for examination. If the undersigned can be of assistance to the Examiner, please contact the undersigned at the number provided below.

Respectfully submitted,

Schering-Plough Corporation
2000 Galloping Hill Road
Patent Department, K-6-1,1990
Kenilworth, NJ 07033
Tel: (908) 298-2266
Fax: (908) 298-5388



Gloria M. Fuentes
Attorney for Applicants
Reg. No. 47,580